ACAD Quote, Financials, Valuation and Earnings

NovaBay Pharmaceuticals has a net margin of 55.37% compared to ACADIA Pharmaceuticals's net margin of -49.65%. ACADIA Pharmaceuticals's return on equity of 41.59% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

ACADIA Pharmaceuticals has a consensus price target of $25.11, signalling upside risk potential of 72.31%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 44.56%. Given that ACADIA Pharmaceuticals has higher upside potential than NovaBay Pharmaceuticals, analysts believe ACADIA Pharmaceuticals is more attractive than NovaBay Pharmaceuticals.

ACADIA Pharmaceuticals has a beta of 0.537, which suggesting that the stock is 46.313% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.897, suggesting its less volatile than the S&P 500 by 10.271%.

ACADIA Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ACADIA Pharmaceuticals pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

ACADIA Pharmaceuticals quarterly revenues are $259.6M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. ACADIA Pharmaceuticals's net income of $143.7M is higher than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, ACADIA Pharmaceuticals's price-to-earnings ratio is 10.71x while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ACADIA Pharmaceuticals is 2.53x versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of 55.37% compared to ACADIA Pharmaceuticals's net margin of --. ACADIA Pharmaceuticals's return on equity of 41.59% beat Palatin Technologies's return on equity of --.

ACADIA Pharmaceuticals has a consensus price target of $25.11, signalling upside risk potential of 72.31%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 1557.59%. Given that Palatin Technologies has higher upside potential than ACADIA Pharmaceuticals, analysts believe Palatin Technologies is more attractive than ACADIA Pharmaceuticals.

ACADIA Pharmaceuticals has a beta of 0.537, which suggesting that the stock is 46.313% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.896, suggesting its less volatile than the S&P 500 by 10.45%.

ACADIA Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ACADIA Pharmaceuticals pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

ACADIA Pharmaceuticals quarterly revenues are $259.6M, which are larger than Palatin Technologies quarterly revenues of --. ACADIA Pharmaceuticals's net income of $143.7M is higher than Palatin Technologies's net income of --. Notably, ACADIA Pharmaceuticals's price-to-earnings ratio is 10.71x while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ACADIA Pharmaceuticals is 2.53x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Retractable Technologies has a net margin of 55.37% compared to ACADIA Pharmaceuticals's net margin of -18.58%. ACADIA Pharmaceuticals's return on equity of 41.59% beat Retractable Technologies's return on equity of -16.83%.

ACADIA Pharmaceuticals has a consensus price target of $25.11, signalling upside risk potential of 72.31%. On the other hand Retractable Technologies has an analysts' consensus of -- which suggests that it could fall by --. Given that ACADIA Pharmaceuticals has higher upside potential than Retractable Technologies, analysts believe ACADIA Pharmaceuticals is more attractive than Retractable Technologies.

ACADIA Pharmaceuticals has a beta of 0.537, which suggesting that the stock is 46.313% less volatile than S&P 500. In comparison Retractable Technologies has a beta of 2.279, suggesting its more volatile than the S&P 500 by 127.852%.

ACADIA Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Retractable Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ACADIA Pharmaceuticals pays -- of its earnings as a dividend. Retractable Technologies pays out -1.94% of its earnings as a dividend.

ACADIA Pharmaceuticals quarterly revenues are $259.6M, which are larger than Retractable Technologies quarterly revenues of $10.3M. ACADIA Pharmaceuticals's net income of $143.7M is higher than Retractable Technologies's net income of -$1.9M. Notably, ACADIA Pharmaceuticals's price-to-earnings ratio is 10.71x while Retractable Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ACADIA Pharmaceuticals is 2.53x versus 0.63x for Retractable Technologies. Usually stocks with elevated PS ratios are considered overvalued.

SpringWorks Therapeutics has a net margin of 55.37% compared to ACADIA Pharmaceuticals's net margin of -125.59%. ACADIA Pharmaceuticals's return on equity of 41.59% beat SpringWorks Therapeutics's return on equity of -46.69%.

ACADIA Pharmaceuticals has a consensus price target of $25.11, signalling upside risk potential of 72.31%. On the other hand SpringWorks Therapeutics has an analysts' consensus of $72.88 which suggests that it could grow by 93.1%. Given that SpringWorks Therapeutics has higher upside potential than ACADIA Pharmaceuticals, analysts believe SpringWorks Therapeutics is more attractive than ACADIA Pharmaceuticals.

ACADIA Pharmaceuticals has a beta of 0.537, which suggesting that the stock is 46.313% less volatile than S&P 500. In comparison SpringWorks Therapeutics has a beta of 0.787, suggesting its less volatile than the S&P 500 by 21.261%.

ACADIA Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. SpringWorks Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ACADIA Pharmaceuticals pays -- of its earnings as a dividend. SpringWorks Therapeutics pays out -- of its earnings as a dividend.

ACADIA Pharmaceuticals quarterly revenues are $259.6M, which are larger than SpringWorks Therapeutics quarterly revenues of $61.5M. ACADIA Pharmaceuticals's net income of $143.7M is higher than SpringWorks Therapeutics's net income of -$77.3M. Notably, ACADIA Pharmaceuticals's price-to-earnings ratio is 10.71x while SpringWorks Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ACADIA Pharmaceuticals is 2.53x versus 14.60x for SpringWorks Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.